Figure 2.
Drugs and targets for anti-inflammatory therapy in atherosclerotic diseases. Tocilizumab is an interleukin-6 receptor antagonist; anakinra is an interleukin 1β receptor antagonist; canakinumab is an interleukin 1β monoclonal antibody; losmapimod is a p38 MAPK inhibitor; everolimus is an mTOR inhibitor; MCC950 is an NLRP3 inflammasome inhibitor; colchicine, methotrexate, and allopurin are broad-spectrum anti-inflammatory drugs.